Alps Advisors Inc Gamida Cell Ltd. Transaction History

Alps Advisors Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$2.2 - $4.46 $159,821 - $324,001	-72,646 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $19,496 - $32,612	-5,064 Reduced 6.52%	72,646 $285,000
Q2 2021 Aug 11, 2021	SELL	$5.85 - $8.33 $171,972 - $244,877	-29,397 Reduced 27.45%	77,710 $498,000
Q1 2021 May 07, 2021	BUY	$7.8 - $12.43 $137,950 - $219,836	17,686 Added 19.78%	107,107 $866,000
Q4 2020 Feb 03, 2021	BUY	$4.07 - $11.0 $363,943 - $983,631	89,421 New	89,421 $750,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.